Blog >
Biopharma

Biopharma

Umbrex is pleased to welcome Pam Fox Rollin with IdeaShape.  Pam Fox Rollin, MBA coaches senior executives and top teams in Silicon Valley and globally. Pam guides technology, biopharma, and healthcare organizations to succeed in strategic transformation, executive development, leadership development, and culture change. She works with public companies, PE-backed companies, scale-ups, and NGOs. She […]

Andrew McKee shares insights about the differences between US and Japan innovation and output in the Biopharma industry. As we’ve expanded our US-Japan services, we are often asked about the differences between the US and Japanese biopharma industry. There are several, and we recently hosted a members-only webinar in Japan about the differences between US […]

Umbrex is pleased to welcome Maria Chevtsova. Maria spent five years in the Boston, New York, and Moscow offices of BCG working on strategic and operational projects with increasing focus on the Healthcare/BioPharma space. She transitioned into industry as an Inhouse Consultant at Merck KGaA and most recently built out and lead Portfolio Strategy and […]

Umbrex is pleased to welcome Rodolphe Lebrun with LDP Partner.  Rodolphe Lebrun is an advisor and interim executive for biotech, medtech and biopharma. He spent 5 years at McKinsey focusing on Life Sciences and led commercial excellence at AbbVie Belgium for 2 years. Prior to McKinsey, he was a R&D project manager in aerospace within […]